Advertisement

Arzneimittel in der Palliativmedizin

  • Klaus RubergEmail author
  • Matthias Thöns
Chapter

Zusammenfassung

Die Arzneimitteltherapie von Palliativpatienten ist eine besondere Herausforderung. Viele Standardtherapien müssen außerhalb von Arzneimittelzulassungen stattfinden, da es für die pharmazeutischen Hersteller häufig wirtschaftlich uninteressant ist, für zumeist generische Wirkstoffe eine neue Zulassung einschließlich der erforderlichen Studien durchzuführen. Anders als in der kurativen Therapie liegt der Fokus in dieser Phase schwerpunktmäßig auf der Linderung von Symptomen. Die Medikation zur Therapie einer Grunderkrankung, die in der letzten Lebensphase keine belastenden Symptome mehr hervorruft, ist in aller Regel verzichtbar. Mit der Kenntnis der palliativmedizinischen Arzneimitteltherapie ist eine gute Symptomkontrolle zu erzielen bei einer gleichzeitigen Vermeidung einer belastenden Polypharmazie.

Literatur

  1. Alt-Epping B, Sitte T, Nauck F, Radbruch L (2010) Sedierung in der Palliativmedizin – Leitlinie für den Einsatz sedierender Maßnahmen in der Palliativversorgung. Z Palliativmed 11:112–122CrossRefGoogle Scholar
  2. Bausewein C, Remi C (2010) Medikamente. In: Bausewein C, Roller S, Voltz R (Hrsg) Leitfaden Palliative Care. Elsevier, München, S 608–650Google Scholar
  3. Bausewein C, Rémi C, Twycross R, Wilcock A (2005) Arzneimitteltherapie in der Palliativmedizin. Elsevier, München, S 1–302Google Scholar
  4. Bausewein C, Delagardelle I, Hentrich M, Langenbach R, Stohscheer I (2012) Gastrointestinale Symptome. In: Aulbert E, Nauck F, Radbruch L (Hrsg) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S 265–300Google Scholar
  5. Bell RFF, Eccleston C, Kalso EA (2017). Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database of Syst Rev 6Google Scholar
  6. van den Beuken‐van Everdingen MH, de Graeff A, Jongen JL, Dijkstra D, Mostovaya I, Vissers KC (2017) national guideline working group “Diagnosis treatment of cancer pain”. Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review. Pain Practice, 17(3), 409–419.Google Scholar
  7. Boyer EW (2010) Serotonin syndrome. UpToDate online January 2010Google Scholar
  8. Boyer EW, Shannon M (2005) The serotonin syndrome. NEJM 352:1112–1120CrossRefGoogle Scholar
  9. Brown C (2010) Drug-induced serotonin syndrome. US Pharmacist 12/21/2010. Medscape onlineGoogle Scholar
  10. Carnahan RM, Lund BC, Perry PJ et al (2006) The Anticholinergic Drug Scale as a measure of drugrelated anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol 46:1481–1486CrossRefGoogle Scholar
  11. Cherny N (2011) Is oral methadone better than placebo or other oral/transdermal opioids in the management of pain? Palliat Med 25:488–493CrossRefGoogle Scholar
  12. Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A (2017) Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009–13. BMJ j359:j4530CrossRefGoogle Scholar
  13. Feddersen B, Rémi C, Vyhnalek B, Lorenzl S (2012) Sicherheit und Wirksamkeit der subcutanen Gabe von Levetiracetam. Palliativmedizin 13:KT_24CrossRefGoogle Scholar
  14. Frechen S, Zoeller A, Ruberg K, Voltz R, Gaertner J (2012) Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany. Drug Saf 35(9):745–758CrossRefGoogle Scholar
  15. Fredheim OM, Moksnes K, Borchgrevink PC, Kaasa S, Dale O (2008) Clinical pharmacology of methadone for pain. Acta Anaesthesiol Scand 52(7):879–889CrossRefGoogle Scholar
  16. Gaertner J, Ruberg K, Schlesiger G, Frechen S, Voltz R (2012) Drug interactions in palliative care – it’s more than cytochrome P450. Palliat Med 26(6):813–825CrossRefGoogle Scholar
  17. Gram-Hansen P, Schultz A (1988) Plasma concentrations following oral and sublingual administration of lorazepam. Int J Clin Pharmacol Ther Toxicol 26(6):323–324PubMedGoogle Scholar
  18. Haroutounian S, McNicol ED, Lipman AG (2012) Methadone for chronic non‐cancer pain in adults. Cochrane database of Syst rev 11Google Scholar
  19. Hatano Y, Matsuoka H, Lam L, & Currow D. C(2018) Side effects of corticosteroids in patients with advanced cancer: a systematic review. Supportive Care in Cancer, 1–5Google Scholar
  20. Haumann J, van Kuijk SM, Geurts JW, Hoebers FJ, Kremer B, Joosten EA, van den Beuken‐van Everdingen MH (2018). Methadone versus Fentanyl in Patients with Radiation‐Induced Nociceptive Pain with Head and Neck Cancer: A Randomized Controlled Noninferiority Trial. Pain Practice, 18(3), 331–340.CrossRefGoogle Scholar
  21. Hawley P, Chow L, Fyles G, Shokoohi A, O‘Leary MJ, Mittelstadt M (2017) Clinical outcomes of start-low, Go-slow methadone initiation for cancer- related pain: What‘s the Hurry?. Journal of palliative medicine, 20(11), 1244–1251.CrossRefGoogle Scholar
  22. Indianapolis Discovery Network for Dementia. Anticholinergic Burden List (ACB). http://www.indydiscoverynetwork.org/resources/ACB%20Scoring%20List_2011%20NC.pdf. Zugegriffen am 08.11.2011
  23. Klockgether-Radke A, Hildebrandt J (1997) Opioid intoxication. Inappropriate administration of transdermal fentanyl. Anaesthesist 46(5):428–429CrossRefGoogle Scholar
  24. Koper D, Kamenski G, Flamm M, Bohmdorfer B, Sonnichsen A (2012) Frequency of medication errors in primary care patients with polypharmacy. Fam Pract 30(3):313–319CrossRefGoogle Scholar
  25. Kusre SR (2011) Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Bet 4: is intranasal fentanyl better than parenteral morphine for managing acute severe pain in children. Emerg Med J 28(12):1077–1078CrossRefGoogle Scholar
  26. Leppert W (2009) The role of methadone in cancer pain treatment – a review. Int J Clin Pract 63(7):1095–1109CrossRefGoogle Scholar
  27. Madden K, Bruera E (2017) Very-low-dose methadone to treat refractory neuropathic pain in children with cancer. Journal of palliative medicine, 20(11), 1280–1283.CrossRefGoogle Scholar
  28. Mehlis K, Winkler EC (2016) Ethische Analyse lebensverlängernder Behandlungen. Onkologe 22(11):844–851CrossRefGoogle Scholar
  29. Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515CrossRefGoogle Scholar
  30. Molassiotis A, Smith JA, Mazzone P, Blackhall F, Irwin RS, Panel CEC (2017) Symptomatic treatment of cough among adult patients with lung cancer: CHEST guideline and expert panel report. Chest 151(4):861–874CrossRefGoogle Scholar
  31. Nauck F, Radbruch L (2012) Systemische medikamentöse Schmerztherapie. In: Aulbert E, Nauck F, Radbruch L (Hrsg) Lehrbuch der Palliativmedizin. Schattauer, Stuttgart, S 175–207Google Scholar
  32. Neitzke G, Oehmichen F, Schliep HJ, Wördehoff D (2010) Sedierung am Lebensende. Empfehlungen der AG Ethik am Lebensende in der Akademie für Ethik in der Medizin (AEM). Ethik Med 22(2):139–147CrossRefGoogle Scholar
  33. Nicholson AB, Watson GR, Derry S, Wiffen PJ (2017) Methadone for cancer pain. Cochrane Database Syst Rev 2:CD003971.  https://doi.org/10.1002/14651858.CD003971 CrossRefPubMedGoogle Scholar
  34. Niesters M, Martini C, Dahan A (2013) Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol.  https://doi.org/10.1111/bcp.12094 CrossRefGoogle Scholar
  35. O’Mahoni D, O’Connor MN (2011) Pharmakotherapy at the end-of-life. Age Ageing 40(4):419–422CrossRefGoogle Scholar
  36. Orentlicher JD (1997) The supreme court and physician-assisted suicide. Sounding Board. N Engl J Med 337:1236–1239CrossRefGoogle Scholar
  37. Quigley C (2004) Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev (3):CD004847Google Scholar
  38. Roller S (2010) Arbeitstechniken. In: Leitfaden Palliative Care, 4. Aufl. Elsevier, München, S 183–182Google Scholar
  39. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE (2008) The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 168:508–513CrossRefGoogle Scholar
  40. Sitte T, Bausewein C (2008) Intranasal fentanyl for episodic breathlessness. J Pain Symptom 36(6):e3–e6CrossRefGoogle Scholar
  41. Sloots CE, Rykx A, Cools M, Kerstens R, De Pauw M (2010) Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci 55(10):2912–2921CrossRefGoogle Scholar
  42. Sutherland A, Naessens K, Plugge E, Ware L, Head K, Burton MJ, Wee B (2018) Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults. Cochrane Database of Syst Rev 9Google Scholar
  43. Tanguy-Goarin C, Cogluet V (2010) Drugs administration by subcutaneous injection within palliative care. Therapie 65(6):525–531CrossRefGoogle Scholar
  44. Thöns M, Sitte T, Gastmeier K, Tolmein O, Zenz M (2010) Therapieempfehlungen in der Palliativmedizin zumeist zulassungsüberschreitend (off label). Abstract 8. Kongress der Deutschen Gesellschaft für Palliativmedizin, Dresden 10.09.2010Google Scholar
  45. Vissers D, Stam W, Nolte T, Lenre M, Jansen J (2010) Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 26(5):1037–1045CrossRefGoogle Scholar
  46. Zarowitz BJ (2006) Oral solid potassium chloride and anticholinergic medications: a new drug interaction for an old drug? Geriatr Nurs 27:329–333CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Kronen-Apotheke-MarxenMarxen-Ruberg OHGWesselingDeutschland
  2. 2.Palliativnetz Witten e.V.WittenDeutschland

Personalised recommendations